Medtronic Infuse BMP Cancer Risk
In recent years, there have been increasing concerns over the risk of cancer from the Medtronic Infuse bone growth protein. The product liability lawyers at Saiontz & Kirk, P.A. are evaluating the potential for Medtronic Infuse cancer lawsuits on behalf of individuals diagnosed with:
- Breast Cancer
- Pancreatic Cancer
- Prostate Cancer
- Other Cancer or Tumor
Potential claims are also being investigated on behalf of individuals who experienced nerve damage, inflammation, respiratory problems and other complications following Medtronic Infuse BMP surgery, which may have been caused by excess bone growth around the spine.
To review a potential lawsuit for yourself, a friend or family member request a free consultation and claim evaluation.
Medtronic Infuse Cancer Side Effects
Have You or a Loved One Experienced Medtronic Infuse Problems?
Medtronic Infuse is a genetically engineered protein, known as rhBMP-2, which is often implanted into the spine to encourage bone growth and fusion of vertebrae in the spine.
During spinal surgery, Medtronic Infuse is only approved for the limited use during single-level, lumbar fusions involving an anterior approach. However, the product has been widely used off-label for other types of back surgeries, which may increase the risk of complications and side effects.
Both federal and independent studies have suggested that side effects of Medtronic Infuse BMP may increase the risk of cancer, as the genetically engineered protein used in Infuse could be a cancer-causing agent.
In 2010, the FDA issued a report on a proposed Medtronic bone product known as Amplify, which also used rhBMP-2. The report found that Amplify recipients had a 5% cancer rate, compared to 1.8% for a control group. Since both Amplify and Infuse use the same protein, concerns surfaced about whether Infuse patients also showed a higher cancer rate.
In November 2011, Dr. Eugene Carragee, editor-in-chief of the Spine Journal, announced findings in a study he conducted that appeared to demonstrate a link between Infuse and increased cancer rates. The study’s findings were announced at a meeting of the North American Spine Society.
Carragee indicated that while Infuse may not be a carcinogen itself, it is tied to a higher rate of cancer among recipients and could be a cancer promoter. The findings suggested that spine surgery patients who receive Medtronic Infuse may be 2.5 times more likely to develop cancer within a year, when compared to those who did not receive Infuse during spinal surgery. The increased risk increased by a factor of five over three years.
Cancers linked to Infuse in the study included breast cancer, pancreatic cancer and prostate cancer.
MEDTRONIC INFUSE CANCER LAWSUITS
The Medtronic Infuse lawyers at Saiontz & Kirk, P.A. represent individuals throughout the United States who are pursuing a product liability lawsuit after experiencing nerve damage and other problems caused by excess bone growth around the spine following a fusion surgery. However, it appears that individuals diagnosed with cancer after Medtronic Infuse BMP surgery may also be entitled to pursue financial compensation.
The potential for litigation over the manufacturer’s failure to adequately warn about the Medtronic Infuse BMP cancer risk is being actively investigated and reviewed by our law firm. As part of our evaluation, we are interested in speaking with individuals diagnosed with cancer after receiving a Medtronic Infuse bone graft implant.
After providing a free consultation and claim evaluation, if it is determined that a lawsuit will be pursued for cancer from Infuse, there are no fees or expenses unless our lawyers are successful obtaining a recovery in your case.